Total Funding
45
40
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
160559
Panbela Therapeutics develops small molecule pharmaceuticals for the oncology and acute care markets.
David B. Kaysen: President, Chief Executive Officer- Thomas Neenan: Co-Founder, Chief Executive Officer & PresidentPast Role: Gray Door Partners, Founding Partner
About the Company
Panbela Therapeutics is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis.
Panbela Therapeutics has scientific collaborations with pancreatic disease experts at Honor
Health in Scottsdale, Arizona, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre, and the Ashford Cancer Centre in Adelaide, Australia.
Founded in 2011, the company is based in Minnesota, United States.
